Research Medical Center, in Kansas City, is proud to be part of the Sarah Cannon Cancer Institute HCA Midwest Health cancer network, providing local access to innovative clinical research trials, tumor profiling and genetic counseling; you can receive top cancer care in the comfort of your community hospital.
As part of the Sarah Cannon Cancer Institute at HCA Midwest Health, Research Medical Center is a network-accredited cancer program. Accredited by the American College of Surgeons’ Commission on Cancer (CoC) quality program, the Sarah Cannon HCA Midwest Health cancer centers exceed the quality care standards set out by the CoC and consistently provide excellence in the delivery of comprehensive patient-centered care across our network of hospitals.
By addressing patient-centered needs and delivering quality care measured against national standards, patients and families have access to world-class, cutting-edge and innovative oncology services in their local communities. Patients receive the best cancer care close to home, while having access to the latest specialized technologies and clinical trial expertise available across the network.
Building on the strengths of the hospital's existing program, Sarah Cannon at Research Medical Center offers each patient a full range of screening, diagnosis, cancer treatment options and services including a state-of-the-art outpatient facility, a dedicated inpatient oncology unit and unparalleled specialized expertise.
Sarah Cannon at Research Medical Center in Kansas City is renowned for its advanced technologies and resources such as the area’s only Gamma Knife® treatment for brain tumors and the Liver and Pancreas Institute, dedicated to the treatment of cancers of the liver and biliary tract. We pride ourselves on having the most advanced technologies such as image-guided brachytherapy, linear accelerators to deliver image-guided intensity modulated radiation therapy, a 16-slice intra-operative big bore CT scanner, a 64-slice CT scanner for the clearest images to diagnose and stage tumors for treatment, and advanced cancer treatments such as Mammosite® for breast cancer.
Free Risk Assessments
Eating right and exercising are great steps toward leading a healthy life, but did you know your family history, age, and countless other factors can still put you at risk for health problems? Try our free risk assessments below to estimate your personal risk of developing breast, colon or rectal cancer, and identify your different types of risk factors.
- Low-Dose CT Scan for lung cancer screening
For more information, contact us at (816) 276-4700 or visit hcamidwest.com. For cancer-related wellness opportunities, Research Medical Center offers patients a variety of wellness services at the Center for Integrative Therapy.
In addition to comprehensive prevention tools, diagnostics, cutting-edge therapies and surgical treatments, Sarah Cannon Cancer Institute HCA Midwest Health also offers a cancer wellness program to help support you every step of the way.
The Cancer Programs Practice Profile Reports (CP3R) is a set of six unified measures* for breast and colorectal cancer.
The CP3R data is provided to healthcare facilities to help them:
- ensure patients are treated according to recognized standards of care,
- promote quality improvement activities to facilitate fulfillment of CoC accreditation standards, and
- accurately compare clinical performance among CoC accredited cancer programs.
Sarah Cannon at Research Medical Center is above the national rate for all six measures.
*The six measures were agreed upon by the NQF (National Quality Forum) facilitated an agreement between the CoC (Commission on Cancer), ASCO (American Society for Clinical Oncology) & NCCN (National Comprehensive Cancer Network).
Source: Commission on Cancer, National Cancer Database
|Quality Measure||Research Medical Center 2011||Missouri 2011||National 2011|
|Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis of breast cancer for women with 4 or more positive regional lymph nodes||100%||84.4%||79.8%|
|Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer||100%||94.8%||92.2%|
|Tamoxifen or third generation aromatase inhibitor (hormone therapy) is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c N0 M0 or Stage II or Stage III ERA and/or PRA positive breast cancer||97.5%||93.6%||91.1%|